Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ... [Yahoo! Finance]
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: Yahoo! Finance
Research and Development Expenses : R&D expenses increased to $189.6 million in 2023 from $172.7 million in 2022. General and Administrative Expenses : G&A expenses rose to $64.4 million in 2023, up from $54.6 million in the previous year. Net Loss : Zentalis reported a net loss of $292.3 million for the year, compared to a net loss of $237.1 million in 2022. Clinical Development : Multiple clinical catalysts for azenosertib expected in 2024, with plans to submit an NDA in 2026. Leadership Team Strengthened : New appointments include Diana Hausman, M.D., as Chief Medical Officer and Kyle Rasbach, Ph.D., Pharm.D., as Chief Business Officer. Warning! GuruFocus has detected 2 Warning Sign with ZNTL. Zentalis Pharmaceuticals Inc ( NASDAQ:ZNTL ) released its 8-K filing on February 27, 2024, detailing the company's financial results for the full year ended December 31, 2023, and providing updates on its operational achievements. Zentalis, a clinical-stage biopharmaceutical comp
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit [Yahoo! Finance]Yahoo! Finance
- Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation SummitGlobeNewswire
- Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its price target lowered by analysts at HC Wainwright from $46.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its price target lowered by analysts at Stifel Nicolaus from $36.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock [Yahoo! Finance]Yahoo! Finance
ZNTL
Earnings
- 5/7/24 - Beat
ZNTL
Sec Filings
- 5/9/24 - Form 144
- 5/9/24 - Form 4
- 5/7/24 - Form 10-Q
- ZNTL's page on the SEC website